RESEARCH

Eyes & visual function

See also:
– A letter regarding finasteride from Keshav Narain, MD, an ophthalmologist at South Bay Retina in San Jose, California
– Related research: Ophthalmology

General

Fraunfelder, F. Chapter 11: Hormones and drugs affecting hormonal mechanisms. Drug-Induced Ocular Side Effects. 8th Edition. Elsevier; 2020. doi:10.1016/B978-0-323-65375-6.00011-6

Nguyen LH, Makino A, Namkoong P, Yiannakou Y, Narain K. Finasteride induced clinical ocular toxicity (ARVO Annual Meeting Abstract). Investigative Ophthalmology & Visual Science. 2018. Abstract • Poster • Summary on South Bay Retina website • A letter regarding finasteride

[Background] Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol. 2000. doi:10.1136/bjo.84.1.76 • PubMed • PMC full text

Cataract

Chou SY, Kao SC, Hsu WM. Propecia-associated bilateral cataract. Clin Exp Ophthalmol. 2004. doi:10.1046/j.1442-9071.2004.00770.x • PubMed

Dry eye / meibomian gland dysfunction

Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000. doi:10.1210/jcem.85.12.7072 • PubMed

Li K, Zhang C, Yang Z, Wang Y, Si H. Evaluation of a novel dry eye model induced by oral administration of finasteride. Mol Med Rep. 2017. doi:10.3892/mmr.2017.7754 • PubMed

Nguyen BJ, Meer E, Gupta AS, et al. The effect of finasteride on dry eye disease. Paper presented at: ARVO 2022: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 1, 2022; Denver, CO. Abstract (PDF)

Singh S, Moksha L, Sharma N, Titiyal JS, Biswas NR, Velpandian T. Development and evaluation of animal models for sex steroid deficient dry eye. J Pharmacol Toxicol Methods. 2014. doi:10.1016/j.vascn.2014.03.004 • PubMed

Zhang C, Li K, Yang Z, Wang Y, Si H. The effect of the aqueous extract of Bidens pilosa L. on androgen deficiency dry eye in rats. Cell Physiol Biochem. 2016. doi:10.1159/000445622 • PubMed

Intraoperative floppy iris syndrome

Calvao J, Feijão J, Soares RO. Finasteride and floppy iris syndrome: What role can the dermatologist play? Int J Trichology. 2022. doi:10.4103/ijt.ijt_118_20 • PubMed • PMC full text

Chatziralli IP, Peponis V, Parikakis E, Maniatea A, Patsea E, Mitropoulos P. Risk factors for intraoperative floppy iris syndrome: a prospective study. Eye (Lond). 2016. doi:10.1038/eye.2016.122 • PubMed • PMC full text

Chatziralli IP, Sergentanis TN, Papazisis L, Moschos MM. Risk factors for intraoperative floppy iris syndrome: a retrospective study. Acta Ophthalmol. 2012. doi:10.1111/j.1755-3768.2011.02132.x • PubMed

Christou CD, Esagian SM, Ziakas N, Prousali E, Tzamalis A. Factors predisposing to Intraoperative Floppy Iris Syndrome (IFIS): an updated systematic review and meta-analysis. J Cataract Refract Surg. 2022. doi:10.1097/j.jcrs.0000000000001017 • PubMed

Horvath K, Vultur F, Simon V, Voidazan S, Mühlfay G. Research on intraoperative iris behavior in rabbits treated with tamsulosin and finasteride. Hippokratia. 2015. PubMed • PMC full text

Issa SA, Dagres E. Intraoperative floppy iris syndrome and finasteride intake. J Cataract Refect Surg. 2007. doi:10.1016/j.jcrs.2007.07.025 • PubMed

Kaczmarek IA, Prost ME, Wasyluk J. Clinical risk factors associated with intraoperative floppy iris syndrome: a prospective study. Int Ophthalmol. 2019. doi:10.1007/s10792-018-0840-3 • PubMed

Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011. doi:10.1016/j.jcrs.2011.04.013 • PubMed

Yeu E, Grostern R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2007. doi:10.1016/j.jcrs.2006.12.032 • PubMed

Ischemic optic neuropathy

Lee JW, Lee HJ. Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma. Cutan Ocul Toxicol. 2013. doi:10.3109/15569527.2012.733788

Macular conditions

Lombardo R, Loraschi A, Lecchini S, Cosentino M. Finasteride-associated central serious chorioretinopathy. Drug Safety. 2008. doi:10.2165/00002018-200831100-00098

Shin YK, Lee GW, Kang SW, Kim SJ, Kim AY. Macular abnormalities associated with 5α-reductase inhibitor. JAMA Ophthalmol. 2020. doi:10.1001/jamaophthalmol.2020.1279 • PubMed

[Letter] Burgos-Blasco B, Burgos-Blasco P. Macular abnormalities associated with 5α-reductase inhibitor. JAMA Ophthalmol. 2021 Feb 1. doi:10.1001/jamaophthalmol.2020.5768 • PubMed

[Reply] Shin YK, Kang SW. Macular abnormalities associated with 5α-reductase inhibitor—Reply. JAMA Ophthalmol. 2021 Feb 1. doi:10.1001/jamaophthalmol.2020.5774 • PubMed

Ophthalmoparesis

Ryu HJ, Kwon DY. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia. Dermatol Surg. 2014. doi:10.1111/dsu.12458 • PubMed